Bristol-Myers Squibb CapEx decreased by 6.2% to $347.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 33.5%, from $260.00M to $347.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows an upward trend with a 7.7% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $210.00M | $270.00M | $320.00M | $253.00M | $272.00M | $247.00M | $346.00M | $278.00M | $259.00M | $342.00M | $330.00M | $284.00M | $262.00M | $324.00M | $378.00M | $260.00M | $361.00M | $320.00M | $370.00M | $347.00M |
| QoQ Change | — | +28.6% | +18.5% | -20.9% | +7.5% | -9.2% | +40.1% | -19.7% | -6.8% | +32.0% | -3.5% | -13.9% | -7.7% | +23.7% | +16.7% | -31.2% | +38.8% | -11.4% | +15.6% | -6.2% |
| YoY Change | — | — | — | — | +29.5% | -8.5% | +8.1% | +9.9% | -4.8% | +38.5% | -4.6% | +2.2% | +1.2% | -5.3% | +14.5% | -8.5% | +37.8% | -1.2% | -2.1% | +33.5% |